in this issue
Pharma/Fine Chemicals Roundup – September 6
6:30 AM MDT | September 6, 2011 | By DEEPTI RAMESH
DSM AND SINOCHEM ESTABLISH ANTI-INFECTIVES JV
DSM and Sinochem have established the previously announced 50-50 joint venture for the DSM Anti-Infectives business. The necessary regulatory approvals and customary clearances from competition authorities have been received, DSM says. Sinochem, as part of the deal, has acquired a 50% stake in DSM Anti-Infectives for €210 million. The deal is retroactive to January 1, 2011. DSM Anti-Infectives develops, produces, and sells raw materials, intermediates and active pharmaceutical ingredients (API) for anti-infectives such as antibiotics, anti-fungals, and APIs for other therapeutic classes like cholesterol lowering medicines. Plans for the jv were first announced in December 2010.
The new jv dubbed DSM Sinochem Pharmaceuticals will be headquartered in Hong Kong, and it includes all current activities of DSM Anti-Infectives across the world. The 2000 employees of DSM Anti-Infectives will become part of the jv.
“The establishment of this joint venture with Sinochem is fully in line with DSM’s stated strategy for its Pharma cluster: creating value via partnerships, but also further strengthens DSM’s position in China,” says Stefan Doboczky, member of the managing board of DSM, and CEO of DSM Sinochem Pharmaceuticals. “The combination of DSM's strong global market position in anti-infectives and Sinochem's significant global market capability, presents exciting future growth opportunities through combined technologies and access to customers, especially in the fast growing Asian economies.”
DMV-FONTERRA EXCIPIENTS TO ACQUIRE INDIAN FIRM
DMV-Fonterra Excipients (Goch, Germany), a manufacturer of excipients for the pharmaceutical industry, says it has signed a business transfer agreement for the acquisition of the business and assets of Brahmar Cellulose (Cuddalore, India), a producer of pharmaceutical microcrystalline cellulose and sodium carboxyl methyl cellulose. Financial details of the deal were not disclosed. The acquisition is expected to be completed in the fourth quarter of 2011.
The acquisition will create a unique market position for DMV-Fonterra as the sole manufacturer and supplier of the most commonly used diluents and superdisintegrants to the pharmaceutical industry, the company says.
“The acquisition of Brahmar Cellulose is a further step in achieving our ambition to become a leading supplier in pharmaceutical excipients and will give a stronger base for future developments in this area,” says Jan Jongsma, CEO of DMV-Fonterra.
DMV-Fonterra Excipients is a 50-50 joint venture between dairy companies FrieslandCampina (Amersfoort, the Netherlands) and Fonterra (Auckland, New Zealand).
U.S. PHARMACOPEIAL CONVENTION EXPANDS FACILITY IN INDIA
The United States Pharmacopeial Convention (USP; Rockville, MD) says it has expanded its facility in the IKP Knowledge Park at Hyderabad, India. USP is a scientific non-profit organization that sets standards for the quality, purity, identity, and strength of medicines, food ingredients, and dietary supplements manufactured and sold worldwide. USP opened its first non-U.S. facility at Hyderabad in 2005. The number of employees at the expanded facility at Hyderabad will increase from 70 to 90 in the coming year, USP says.
“The new facility is a milestone in our constructive relationships with Indian government and industry,” says Roger L. Williams, CEO of USP. “This expands our scope considerably. We are now poised to do more collaborative testing, verification testing, pharmacopeial education, customer support, and sourcing of written and physical standards for drugs, much of which we have been doing in concert with Indian manufacturers. In addition, we are now able to launch new initiatives in synthetic chemistry and, reflecting the increasingly important role worldwide of biologics and biotechnology, in bio-analytic chemistry and testing.”
OXFORD BIOTHERAPEUTICS LICENSES LONZA’S GS GENE EXPRESSION SYSTEM
Lonza says it has signed a non-exclusive license agreement with biotechnology company Oxford BioTherapeutics (OBT; Abingdon, U.K.) that will provide OBT with access to Lonza’s GS Gene Expression System. The agreement covers the research, development and commercial use of the GS system by OBT. Financial details of the deal were not disclosed. The GS Gene Expression System is used for the production of therapeutic recombinant proteins and monoclonal antibodies.